This article discusses the fact that Janet Woodcock of the FDA is looking for therapeutics that can complete testing and have drug available to reach the market before 2021. Certainly seems like IPIX is trying to meet these criteria. It also suggests that FDA is addressing prophylaxis, in-patient, out patient etc.

https://endpts.com/more-warp-speed-contracts-...0officials